RALLYBIO CORPORATION Payments to Acquire Marketable Securities
RALLYBIO CORPORATION (RLYB) reported Payments to Acquire Marketable Securities of $0 for the 6-month period ending 2026-06-30, per its S-4/A filed 2026-08-26.
Financial Statements › Cash Flow › Investing Activities
us-gaap:PaymentsToAcquireMarketableSecurities · last filed 2026-08-26
- RALLYBIO CORPORATION payments to acquire marketable securities for the quarter ending 2026-06-30 was $0.00, a 100.00% decline year-over-year.
- RALLYBIO CORPORATION payments to acquire marketable securities for the quarter ending 2026-03-31 was $0.00, a 100.00% decline year-over-year.
- RALLYBIO CORPORATION payments to acquire marketable securities for the quarter ending 2025-12-31 was $7.08M, a 59.16% decline year-over-year.
- RALLYBIO CORPORATION payments to acquire marketable securities for the quarter ending 2025-09-30 was $738.00K, a 57.07% decline year-over-year.
- RALLYBIO CORPORATION payments to acquire marketable securities for fiscal 2023 was $108.41M, a 46.15% decline from fiscal 2022.
- RALLYBIO CORPORATION payments to acquire marketable securities for fiscal 2022 was $201.32M.
- RALLYBIO CORPORATION payments to acquire marketable securities for fiscal 2021 was $0.00.
| Period end | Payments to Acquire Marketable Securities 3 month | Payments to Acquire Marketable Securities 6 month | Payments to Acquire Marketable Securities 9 month | Payments to Acquire Marketable Securities 12 month |
|---|---|---|---|---|
| 2026-06-30 | $0.00 derived: S-4/A 6 month − S-4 3 month · filed 2026-08-26 | $0.00 S-4/A · filed 2026-08-26 | $7.08M derived: sum of 3 quarters · filed 2026-08-26 | $7.81M derived: sum of 4 quarters · filed 2026-08-26 |
| 2026-03-31 | $0.00 S-4 · filed 2026-07-15 | $7.08M derived: sum of 2 quarters · filed 2026-08-26 | $7.81M derived: sum of 3 quarters · filed 2026-08-26 | $11.78M derived: sum of 4 quarters · filed 2026-08-26 |
| 2025-12-31 | $7.08M derived: S-4/A 12 month − 10-Q 9 month · filed 2026-08-26 | $7.81M derived: sum of 2 quarters · filed 2026-08-26 | $11.78M derived: sum of 3 quarters · filed 2026-08-26 | $17.70M S-4/A · filed 2026-08-26 |
| 2025-09-30 | $738.00K derived: 10-Q 9 month − S-4/A 6 month · filed 2025-11-06 | $4.70M derived: sum of 2 quarters · filed 2026-08-26 | $10.62M 10-Q · filed 2025-11-06 | $27.95M derived: sum of 4 quarters · filed 2026-08-26 |
| 2025-06-30 | $3.96M derived: S-4/A 6 month − S-4 3 month · filed 2026-08-26 | $9.88M S-4/A · filed 2026-08-26 | $27.21M derived: sum of 3 quarters · filed 2026-08-26 | $28.93M derived: sum of 4 quarters · filed 2026-08-26 |
| 2025-03-31 | $5.92M S-4 · filed 2026-07-15 | $23.24M derived: sum of 2 quarters · filed 2026-08-26 | $24.96M derived: sum of 3 quarters · filed 2026-08-26 | $44.12M derived: sum of 4 quarters · filed 2026-08-26 |
| 2024-12-31 | $17.32M derived: S-4/A 12 month − 10-Q 9 month · filed 2026-08-26 | $19.04M derived: sum of 2 quarters · filed 2026-08-26 | $38.20M derived: sum of 3 quarters · filed 2026-08-26 | $48.93M S-4/A · filed 2026-08-26 |
| 2024-09-30 | $1.72M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $20.87M derived: sum of 2 quarters · filed 2025-11-06 | $31.61M 10-Q · filed 2025-11-06 | $44.35M derived: sum of 4 quarters · filed 2025-11-06 |
| 2024-06-30 | $19.15M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-07 | $29.89M 10-Q · filed 2025-08-07 | $42.63M derived: sum of 3 quarters · filed 2025-08-07 | $76.70M derived: sum of 4 quarters · filed 2025-08-07 |
| 2024-03-31 | $10.74M 10-Q · filed 2025-05-08 | $23.48M derived: sum of 2 quarters · filed 2025-05-08 | $57.55M derived: sum of 3 quarters · filed 2025-05-08 | $89.86M derived: sum of 4 quarters · filed 2025-05-08 |
| 2023-12-31 | $12.74M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-13 | $46.81M derived: sum of 2 quarters · filed 2025-03-13 | $79.13M derived: sum of 3 quarters · filed 2025-03-13 | $108.41M 10-K · filed 2025-03-13 |
| 2023-09-30 | $34.07M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-07 | $66.39M derived: sum of 2 quarters · filed 2024-11-07 | $95.67M 10-Q · filed 2024-11-07 | $160.32M derived: sum of 4 quarters · filed 2024-11-07 |
| 2023-06-30 | $32.32M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08 | $61.60M 10-Q · filed 2024-08-08 | $126.25M derived: sum of 3 quarters · filed 2024-08-08 | $153.82M derived: sum of 4 quarters · filed 2024-08-08 |
| 2023-03-31 | $29.29M 10-Q · filed 2024-05-09 | $93.93M derived: sum of 2 quarters · filed 2024-05-09 | $121.50M derived: sum of 3 quarters · filed 2024-05-09 | $150.46M derived: sum of 4 quarters · filed 2024-05-09 |
| 2022-12-31 | $64.65M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-12 | $92.22M derived: sum of 2 quarters · filed 2024-03-12 | $121.17M derived: sum of 3 quarters · filed 2024-03-12 | $201.32M 10-K · filed 2024-03-12 |
| 2022-09-30 | $27.57M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-09 | $56.53M derived: sum of 2 quarters · filed 2023-11-09 | $136.67M 10-Q · filed 2023-11-09 | $136.67M derived: sum of 4 quarters · filed 2023-11-09 |
| 2022-06-30 | $28.95M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-08 | $109.10M 10-Q · filed 2023-08-08 | $109.10M derived: sum of 3 quarters · filed 2023-08-08 | $109.10M derived: sum of 4 quarters · filed 2023-08-08 |
| 2022-03-31 | $80.14M 10-Q · filed 2023-05-09 | $80.14M derived: sum of 2 quarters · filed 2023-05-09 | $80.14M derived: sum of 3 quarters · filed 2023-05-09 | $80.14M derived: sum of 4 quarters · filed 2023-05-09 |
| 2021-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-06 | $0.00 derived: sum of 2 quarters · filed 2023-03-06 | $0.00 derived: sum of 3 quarters · filed 2023-03-06 | $0.00 10-K · filed 2023-03-06 |
| 2021-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-07 | $0.00 derived: sum of 2 quarters · filed 2022-11-07 | $0.00 10-Q · filed 2022-11-07 | |
| 2021-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-08 | $0.00 10-Q · filed 2022-08-08 | ||
| 2021-03-31 | $0.00 10-Q · filed 2022-05-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Acrivon Therapeutics, Inc. (ACRV) | United States | $0.091B | -1.03 |
| ONCOLYTICS BIOTECH INC (ONCY) | $0.086B | ||
| NEONC TECHNOLOGIES HOLDINGS, INC. (NTHI) | United States | $0.086B | |
| Lexaria Bioscience Corp. (LEXX) | $0.084B | -1.92 | |
| Telomir Pharmaceuticals, Inc. (TELO) | United States | $0.084B | |
| Anixa Biosciences Inc (ANIX) | United States | $0.096B | |
| CITIUS ONCOLOGY, INC. (CTOR) | United States | $0.097B | -1.49 |
| Gain Therapeutics, Inc. (GANX) | United States | $0.080B | -4.40 |
| Milestone Pharmaceuticals Inc. (MIST) | $0.098B | -2.00 | |
| Lifevantage Corp (LFVN) | United States | $0.078B | 15.40 |